REFERENCES
1. Origa R. β-Thalassemia. Genet Med . 2017;19(6):609-619.
doi:10.1038/gim.2016.173
2. Kwiatkowski JL. Hemoglobinopathies. In: Lanzkowsky P, Lipton JM FJ,
ed. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 6th
ed. Elsevier; 2016:188.
3. Stoyanova E, Trudel M, Felfly H et al. Vascular Endothelial
Dysfunction in b-Thalassemia Occurs Despite Increased eNOS Expression
and Preserved Vascular Smooth Muscle Cell Reactivity to NO. PLoS
One . 2012;7(6):38089. doi:10.1371/journal.pone.0038089
4. Paul A, Thomson VS, Refat M et al. Cardiac involvement in
beta-thalassaemia: current treatment strategies. Postgrad Med .
2019;131(4):261-267. doi:10.1080/00325481.2019.1608071
5. Gursel O, Tapan S, Sertoglu E, et al. Elevated plasma asymmetric
dimethylarginine levels in children with beta-thalassemia major may be
an early marker for endothelial dysfunction. Hematology .
2018;23(5):304-308. doi:10.1080/10245332.2017.1396027
6. Cusmà Piccione M, Piraino B, Zito C, et al. Early identification of
cardiovascular involvement in patients with β-thalassemia major.Am J Cardiol . 2013;112(8):1246-1251.
doi:10.1016/j.amjcard.2013.05.080
7. Frimat M, Boudhabhay I, Roumenina LT. toxins Hemolysis Derived
Products Toxicity and Endothelium: Model of the Second Hit. Published
online 2019. doi:10.3390/toxins11110660
8. Morris C, Gladwin M, Kato G. Nitric Oxide and Arginine Dysregulation:
A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders.Curr Mol Med . 2008;8(7):620-632. doi:10.2174/156652408786241447
9. Sandoo A, Veldhuijzen van Zanten JJC., Metsios GS et al. The
Endothelium and Its Role in Regulating Vascular Tone. Open
Cardiovasc Med J . 2015;4(1):302-312. doi:10.2174/1874192401004010302
10. Gambardella J, Khondkar W, Morelli MB et al. Arginine and
endothelial function. Biomedicines . 2020;8(8).
doi:10.3390/BIOMEDICINES8080277
11. Landim MBP, Casella Filho A, Chagas ACP. Asymmetric dimethylarginine
(ADMA) and endothelial dysfunction: Implications for atherogenesis.Clinics . 2009;64(5):471-478. doi:10.1590/S1807-59322009000500015
12. Böger RH, Maas R, Schulze F et al. Asymmetric dimethylarginine
(ADMA) as a prospective marker of cardiovascular disease and
mortality-An update on patient populations with a wide range of
cardiovascular risk. Pharmacol Res . 2009;60(6):481-487.
doi:10.1016/j.phrs.2009.07.001
13. Dogru T, Genc H, Tapan S, et al. Elevated asymmetric
dimethylarginine in plasma: An early marker for endothelial dysfunction
in non-alcoholic fatty liver disease? Diabetes Res Clin Pract .
2012;96(1):47-52. doi:10.1016/j.diabres.2011.11.022
14. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell
specific molecule-1 (ESM-1): A potential novel endothelial cell marker
and a new target for cancer therapy. Biochim Biophys Acta - Rev
Cancer . 2006;1765(1):25-37. doi:10.1016/j.bbcan.2005.08.004
15. Balta S, Mikhailidis DP, Demirkol S et al. Endocan: A novel
inflammatory indicator in cardiovascular disease?Atherosclerosis . 2015;243(1):339-343.
doi:10.1016/j.atherosclerosis.2015.09.030
16. Delehedde M, Devenyns L, Maurage CA et al. Endocan in cancers: A
lesson from a circulating dermatan sulfate proteoglycan. Int J
Cell Biol . Published online 2013. doi:10.1155/2013/705027
17. Cardiac Complications in Thalassaemia Major - Guidelines for the
Management of Transfusion Dependent Thalassaemia (TDT) - NCBI Bookshelf.
Accessed March 11, 2021. https://www.ncbi.nlm.nih.gov/books/NBK269371/
18. Koohi F, Kazemi T, Miri-Moghaddam E. Cardiac complications and iron
overload in beta thalassemia major patients—a systematic review and
meta-analysis. Ann Hematol . 2019;98(6):1323-1331.
doi:10.1007/s00277-019-03618-w
19. Biswas I, Khan GA. Endothelial Dysfunction in Cardiovascular
Diseases. Endothel Dysfunct Cardiovasc Dis . 2014;2014(3):291-308.
www.intechopen.com
20. Haybar H, Shahrabi S, Rezaeeyan H et al. Endothelial Cells: From
Dysfunction Mechanism to Pharmacological Effect in Cardiovascular
Disease. Cardiovasc Toxicol . 2019;19(1):13-22.
doi:10.1007/s12012-018-9493-8
21. Dowsett L, Higgins E, Alanazi S et al. ADMA: A Key Player in the
Relationship between Vascular Dysfunction and Inflammation in
Atherosclerosis. J Clin Med . 2020;9(9):3026.
doi:10.3390/jcm9093026
22. Mohamed ES, Ibrahim B, Amr D et al. Asymmetric dimethylarginine
levels in children with β-thalassemia and their correlations to
tricuspid regurgitant jet velocity. Pediatr Blood Cancer .
2014;61(9):1540-1543. doi:10.1002/pbc.25076
23. Chouliaras GL, Kattamis A, Berdoukas V et al. Cardiac magnetic
resonance in transfusion dependent thalassaemia: Assessment of iron load
and relationship to left ventricular ejection fraction. Br J
Haematol . 2010;151(4):397-401. doi:10.1111/j.1365-2141.2010.08365.x
24. Davis BA, O’Sullivan C, Jarritt PH et al. Value of sequential
monitoring of left ventricular ejection fraction in the management of
thalassemia major. Blood . 2004;104(1):263-269.
doi:10.1182/blood-2003-08-2841
25. Unlu M, Karaman M, Ay SA, et al. The comparative effects of
valsartan and amlodipine on vascular microinflammation in newly
diagnosed hypertensive patients. Clin Exp Hypertens .
2013;35(6):418-423. doi:10.3109/10641963.2012.739237
26. Kali A, Rathan Shetty KS. Endocan: A novel circulating proteoglycan.Indian J Pharmacol . 2014;46(6):579-583.
doi:10.4103/0253-7613.144891
27. Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels
may be a risk factor for the onset of cardiovascular disease: A
meta-analysis. Med (United States) . 2018;97(49).
doi:10.1097/MD.0000000000013407
28. Bessa J, Albino-Teixeira A, Reina-Couto M et al. Endocan: A novel
biomarker for risk stratification, prognosis and therapeutic monitoring
in human cardiovascular and renal diseases. Clin Chim Acta .
2020;509:310-335. doi:10.1016/j.cca.2020.07.041
29. Aggeli C, Antoniades C, Cosma C, et al. Endothelial dysfunction and
inflammatory process in transfusion-dependent patients with
beta-thalassemia major. Int J Cardiol . 2005;105(1):80-84.
doi:10.1016/j.ijcard.2004.12.025
30. Menon P, Kocher O, Aird W. Abstract 15455: Endothelial Cell Specific
Molecule-1 (ESM-1), a Novel Secreted Proteoglycan Stimulates Vascular
Smooth Muscle Cell Proliferation and Migration. undefined .
Published online 2011.
31. Daar S, Al Khabori M, Al Rahbi S et al. Cardiac T2* MR in patients
with thalassemia major: a 10-year long-term follow-up. Ann
Hematol . 2020;99(9):2009-2017. doi:10.1007/s00277-020-04117-z
32. Unsal C. Cardiac Functions and Indicators Of Endothelial Activation
in Patients With Β-Thalassemia Major. Published online 2005.